Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Summary

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Timeline

Start

2017-05-30

Primary completion

2018-07-12

Completion

2018-11-14

Outcome

Missed primary endpoint

registry Risk Difference (RD) 0.078 (95% CI -0.190 to 0.338); Wilson/Newcombe NCT03135548 ↗

Drugs

Indications